310 related articles for article (PubMed ID: 19725597)
1. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events.
Marshall BC; Koch WC
Paediatr Drugs; 2009; 11(5):309-21. PubMed ID: 19725597
[TBL] [Abstract][Full Text] [Related]
2. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.
Reusser P
Expert Opin Investig Drugs; 2001 Sep; 10(9):1745-53. PubMed ID: 11772283
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.
Stockmann C; Roberts JK; Knackstedt ED; Spigarelli MG; Sherwin CM
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):205-19. PubMed ID: 25428442
[TBL] [Abstract][Full Text] [Related]
4. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.
Acosta EP; Brundage RC; King JR; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud G; Whitley R; Kimberlin DW;
Clin Pharmacol Ther; 2007 Jun; 81(6):867-72. PubMed ID: 17392728
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
6. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
Cvetković RS; Wellington K
Drugs; 2005; 65(6):859-78. PubMed ID: 15819597
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
10. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
11. Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies.
Nassetta L; Kimberlin D; Whitley R
J Antimicrob Chemother; 2009 May; 63(5):862-7. PubMed ID: 19287011
[TBL] [Abstract][Full Text] [Related]
12. Antiviral therapy of congenital cytomegalovirus infection.
Schleiss MR
Semin Pediatr Infect Dis; 2005 Jan; 16(1):50-9. PubMed ID: 15685150
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic developments in cytomegalovirus retinitis.
Hoffman VF; Skiest DJ
Expert Opin Investig Drugs; 2000 Feb; 9(2):207-20. PubMed ID: 11060672
[TBL] [Abstract][Full Text] [Related]
14. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.
Amir J; Wolf DG; Levy I
Eur J Pediatr; 2010 Sep; 169(9):1061-7. PubMed ID: 20232081
[TBL] [Abstract][Full Text] [Related]
15. Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring.
Li QY; van den Anker J; Wu YE; Hao GX; Zhao W
Expert Rev Clin Pharmacol; 2023; 16(8):727-739. PubMed ID: 36794592
[TBL] [Abstract][Full Text] [Related]
16. High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations.
Baradhi KM; Aure RL; El-Amm JM
Transplant Proc; 2018; 50(1):142-144. PubMed ID: 29407298
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
Asberg A; Rollag H; Hartmann A
Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
[TBL] [Abstract][Full Text] [Related]
18. [Prolonged treatment with valganciclovir in an infant with congenital cytomegalovirus infection].
Baquero-Artigao F; Romero Gómez MP
An Pediatr (Barc); 2009 Jun; 70(6):578-81. PubMed ID: 19423406
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals.
Segarra-Newnham M; Salazar MI
Pharmacotherapy; 2002 Sep; 22(9):1124-8. PubMed ID: 12222548
[TBL] [Abstract][Full Text] [Related]
20. Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Spinner ML; Lam SW; Koval CE; Athans V
J Clin Virol; 2019 Nov; 120():12-16. PubMed ID: 31514101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
